title: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
abstract: OBJECTIVE
  To determine the efficacy and safety of a newly developed concomitant administration of fludarabine and alemtuzumab (FluCam) in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL).
  
  
  METHODS
  A total of 36 patients were treated in this phase II study (median age, 61.47 years; mean number of prior chemotherapies, 2.6; Binet stage C, n = 28). After an initial dose escalation of alemtuzumab over 3 days, alemtuzumab 30 mg and fludarabine 30 mg/m2 were administered on 3 consecutive days. Treatment was repeated after 28 days for up to six cycles. Restaging (following National Cancer Institute criteria) was carried out after cycles 2 and 4 and 1 month after the end of treatment.
  
  
  RESULTS
  The overall response rate was 83% (11 complete responses, 19 partial responses, one stable disease, and five progressive diseases). Two patients with progressive disease developed fungal pneumonias, and one patient died as a result of Escherichia coli sepsis. Two subclinical cytomegalovirus reactivations occurred.
  
  
  CONCLUSIONS
  The new FluCam regimen is effective and feasible in patients with relapsed and refractory B-CLL.
authors.affiliation: Department of Hematology and Oncology, University of Cologne, Cologne, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Elter
authors.forename: Peter
authors.initials: P
authors.lastname: Borchmann
authors.forename: Holger
authors.initials: H
authors.lastname: Schulz
authors.forename: Marcel
authors.initials: M
authors.lastname: Reiser
authors.forename: Sven
authors.initials: S
authors.lastname: Trelle
authors.forename: Roland
authors.initials: R
authors.lastname: Schnell
authors.forename: Markus
authors.initials: M
authors.lastname: Jensen
authors.forename: Peter
authors.initials: P
authors.lastname: Staib
authors.forename: Timo
authors.initials: T
authors.lastname: Schinköthe
authors.forename: Hartmut
authors.initials: H
authors.lastname: Stützer
authors.forename: Jürgen
authors.initials: J
authors.lastname: Rech
authors.forename: Martin
authors.initials: M
authors.lastname: Gramatzki
authors.forename: Walter
authors.initials: W
authors.lastname: Aulitzky
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Hasan
authors.forename: Andreas
authors.initials: A
authors.lastname: Josting
authors.forename: Michael
authors.initials: M
authors.lastname: Hallek
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D014740:Vidarabine; C024352:fludarabine